Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; and Dicerna Pharmaceuticals, Inc., as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:LLY
Previous Symbol
CUSIP53245710
Phone317-276-2000
Debt
Debt-to-Equity Ratio0.83
Current Ratio1.91
Quick Ratio1.53
Price-To-Earnings
Trailing P/E Ratio26.80
Forward P/E Ratio20.56
P/E Growth1.81
Sales & Book Value
Annual Sales$22.87 billion
Price / Sales5.31
Cash Flow$5.4864 per share
Price / Cash20.91
Book Value$13.36 per share
Price / Book8.59
Profitability
EPS (Most Recent Fiscal Year)$4.28
Net Income$-204,100,000.00
Net Margins1.85%
Return on Equity42.84%
Return on Assets12.64%
Miscellaneous
Employees40,655
Outstanding Shares1,059,320,000
Market Cap$122.68 billion
OptionableOptionable
Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly And Co's stock symbol?
Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?
Eli Lilly And Co announced a quarterly dividend on Monday, October 15th. Shareholders of record on Thursday, November 15th will be paid a dividend of $0.5625 per share on Monday, December 10th. This represents a $2.25 annualized dividend and a yield of 1.96%. The ex-dividend date of this dividend is Wednesday, November 14th. View Eli Lilly And Co's Dividend History.
How were Eli Lilly And Co's earnings last quarter?
Eli Lilly And Co (NYSE:LLY) posted its quarterly earnings results on Tuesday, November, 6th. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.35 by $0.04. The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The firm's quarterly revenue was up 7.1% on a year-over-year basis. During the same period last year, the business earned $1.05 EPS. View Eli Lilly And Co's Earnings History.
When is Eli Lilly And Co's next earnings date?
What guidance has Eli Lilly And Co issued on next quarter's earnings?
Eli Lilly And Co updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $5.55-5.60 for the period, compared to the Thomson Reuters consensus estimate of $5.43. The company issued revenue guidance of $24.3-24.5 billion, compared to the consensus revenue estimate of $24.38 billion.Eli Lilly And Co also updated its FY 2018 guidance to $5.55-5.60 EPS.
What price target have analysts set for LLY?
18 equities research analysts have issued 12 month price objectives for Eli Lilly And Co's shares. Their predictions range from $86.00 to $130.00. On average, they anticipate Eli Lilly And Co's stock price to reach $110.00 in the next year. This suggests that the stock has a possible downside of 4.1%. View Analyst Price Targets for Eli Lilly And Co.
What is the consensus analysts' recommendation for Eli Lilly And Co?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eli Lilly And Co.
What are Wall Street analysts saying about Eli Lilly And Co stock?
Here are some recent quotes from research analysts about Eli Lilly And Co stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month PT for LLY shares to $128 from $110. The increase in our PT is driven by multiple expansion. We think this is deserved because continued sales growth, margin expansion, and pipeline advancements are still underappreciated, in our opinion." (10/17/2018)
- 2. According to Zacks Investment Research, "Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo are expected to drive revenues. Lilly expects to launch 20 new products by 2023, including at least two new indications/line extensions on average every year. Lilly is having a strong year in terms of its pipeline with several positive late-stage data readouts. The newly approved migraine treatment Emgality could emerge as a significant contributor to long term growth. Lilly has also added promising new assets through business development deals. The stock has outperformed the industry this year so far. However, competitive pressure on Lilly’s drugs is rising. Challenges remain for the company in the form of generic competition for several drugs including Cialis and rising pricing pressure in the diabetes franchise. Estimates have gone up ahead of the Q3 earnings release. Lilly has a positive record of earnings surprises in recent quarters." (10/9/2018)
Has Eli Lilly And Co been receiving favorable news coverage?
Media headlines about LLY stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Eli Lilly And Co earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Are investors shorting Eli Lilly And Co?
Eli Lilly And Co saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 11,188,263 shares, a drop of 26.5% from the October 15th total of 15,215,133 shares. Based on an average trading volume of 4,142,975 shares, the days-to-cover ratio is currently 2.7 days. Approximately 1.2% of the company's shares are short sold. View Eli Lilly And Co's Current Options Chain.
Who are some of Eli Lilly And Co's key competitors?
Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Sanofi (SNY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Shire (SHPG), Allergan (AGN), Celgene (CELG) and Zoetis (ZTS).
Who are Eli Lilly And Co's key executives?
Eli Lilly And Co's management team includes the folowing people:
- Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
- Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
- Mr. Enrique A. Conterno, Sr. VP (Age 51)
- Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)
- Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin.
Who are Eli Lilly And Co's major shareholders?
Eli Lilly And Co's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.12%), BlackRock Inc. (6.23%), Primecap Management Co. CA (5.17%), Franklin Resources Inc. (2.23%), Dodge & Cox (2.14%) and Capital International Investors (0.97%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Derica W Rice, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.
Which institutional investors are selling Eli Lilly And Co stock?
LLY stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Dodge & Cox, Lilly Endowment Inc., Massachusetts Financial Services Co. MA, Mitsubishi UFJ Trust & Banking Corp, Janus Henderson Group PLC, Schroder Investment Management Group and Point72 Asset Management L.P.. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.
Which institutional investors are buying Eli Lilly And Co stock?
LLY stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, TIAA CREF Investment Management LLC, AQR Capital Management LLC, Capital International Investors, PNC Financial Services Group Inc., Capital World Investors, Teachers Advisors LLC and Capital Growth Management LP. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly And Co.
How do I buy shares of Eli Lilly And Co?
Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly And Co's stock price today?
One share of LLY stock can currently be purchased for approximately $114.72.
How big of a company is Eli Lilly And Co?
Eli Lilly And Co has a market capitalization of $122.68 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.
What is Eli Lilly And Co's official website?
How can I contact Eli Lilly And Co?
Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
